Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas

Bruce D. Cheson, Sandra J. Horning, Bertrand Coiffier, Margaret A. Shipp, Richard I. Fisher, Joseph M. Connors, T. Andrew Lister, Julie Marie Vose, Antonio Grillo-López, Anton Hagenbeek, Fernando Cabanillas, Donald Klippensten, Wolfgang Hiddemann, Ronald Castellino, Nancy L. Harris, James Olen Armitage, William Carter, Richard Hoppe, George P. Canellos

Research output: Contribution to journalArticle

2937 Citations (Scopus)

Abstract

Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients-especially those with large-cell NHL - who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and became more widely available.

Original languageEnglish (US)
Pages (from-to)1244-1253
Number of pages10
JournalJournal of Clinical Oncology
Volume17
Issue number4
StatePublished - Apr 1 1999

Fingerprint

Non-Hodgkin's Lymphoma
Education
Clinical Trials
Guidelines
Gallium
Radiation Oncology
Medical Oncology
Hematology
Single-Photon Emission-Computed Tomography
Radiology
Cytogenetics
Disease-Free Survival
Lymphoma
Therapeutics
Lymph Nodes
Communication
Tomography
Research Personnel
Pathology
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., ... Canellos, G. P. (1999). Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology, 17(4), 1244-1253.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. / Cheson, Bruce D.; Horning, Sandra J.; Coiffier, Bertrand; Shipp, Margaret A.; Fisher, Richard I.; Connors, Joseph M.; Lister, T. Andrew; Vose, Julie Marie; Grillo-López, Antonio; Hagenbeek, Anton; Cabanillas, Fernando; Klippensten, Donald; Hiddemann, Wolfgang; Castellino, Ronald; Harris, Nancy L.; Armitage, James Olen; Carter, William; Hoppe, Richard; Canellos, George P.

In: Journal of Clinical Oncology, Vol. 17, No. 4, 01.04.1999, p. 1244-1253.

Research output: Contribution to journalArticle

Cheson, BD, Horning, SJ, Coiffier, B, Shipp, MA, Fisher, RI, Connors, JM, Lister, TA, Vose, JM, Grillo-López, A, Hagenbeek, A, Cabanillas, F, Klippensten, D, Hiddemann, W, Castellino, R, Harris, NL, Armitage, JO, Carter, W, Hoppe, R & Canellos, GP 1999, 'Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas', Journal of Clinical Oncology, vol. 17, no. 4, pp. 1244-1253.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology. 1999 Apr 1;17(4):1244-1253.
Cheson, Bruce D. ; Horning, Sandra J. ; Coiffier, Bertrand ; Shipp, Margaret A. ; Fisher, Richard I. ; Connors, Joseph M. ; Lister, T. Andrew ; Vose, Julie Marie ; Grillo-López, Antonio ; Hagenbeek, Anton ; Cabanillas, Fernando ; Klippensten, Donald ; Hiddemann, Wolfgang ; Castellino, Ronald ; Harris, Nancy L. ; Armitage, James Olen ; Carter, William ; Hoppe, Richard ; Canellos, George P. / Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 4. pp. 1244-1253.
@article{6ee97a4cce3c4f908b168fc2214d3e38,
title = "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas",
abstract = "Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75{\%} reduction in tumor size after therapy but with a residual mass, to include patients-especially those with large-cell NHL - who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and became more widely available.",
author = "Cheson, {Bruce D.} and Horning, {Sandra J.} and Bertrand Coiffier and Shipp, {Margaret A.} and Fisher, {Richard I.} and Connors, {Joseph M.} and Lister, {T. Andrew} and Vose, {Julie Marie} and Antonio Grillo-L{\'o}pez and Anton Hagenbeek and Fernando Cabanillas and Donald Klippensten and Wolfgang Hiddemann and Ronald Castellino and Harris, {Nancy L.} and Armitage, {James Olen} and William Carter and Richard Hoppe and Canellos, {George P.}",
year = "1999",
month = "4",
day = "1",
language = "English (US)",
volume = "17",
pages = "1244--1253",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas

AU - Cheson, Bruce D.

AU - Horning, Sandra J.

AU - Coiffier, Bertrand

AU - Shipp, Margaret A.

AU - Fisher, Richard I.

AU - Connors, Joseph M.

AU - Lister, T. Andrew

AU - Vose, Julie Marie

AU - Grillo-López, Antonio

AU - Hagenbeek, Anton

AU - Cabanillas, Fernando

AU - Klippensten, Donald

AU - Hiddemann, Wolfgang

AU - Castellino, Ronald

AU - Harris, Nancy L.

AU - Armitage, James Olen

AU - Carter, William

AU - Hoppe, Richard

AU - Canellos, George P.

PY - 1999/4/1

Y1 - 1999/4/1

N2 - Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients-especially those with large-cell NHL - who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and became more widely available.

AB - Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients-especially those with large-cell NHL - who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and became more widely available.

UR - http://www.scopus.com/inward/record.url?scp=0042449063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042449063&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 1244

EP - 1253

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -